logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Okays Novel Use Of Avastin For Treating Metastatic Colorectal Cancers

Genentech, a member of the Roche Group (RHHBY.PK), announced Wednesday that the U.S. Food and Drug Administration or FDA has approved the use of Avastin in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy, for the treatment of people ailing from metastatic colorectal cancer or mCRC.

Commenting on the approval, Hal Barron, chief medical officer and head of Global Product Development stated, "These people now have the option to continue with Avastin, plus a new chemotherapy after their cancer worsens, which may help them live longer than changing to the new chemotherapy alone."

The company said that Avastin was the only biologic medicine approved by the FDA for the treatment of people with mCRC in combination with intravenous 5FU-based chemotherapy as an initial treatment, as treatment for people whose cancer worsened after chemotherapy alone, and now as a treatment for people whose cancer has worsened after initial treatment with an Avastin-based regimen.

Avastin which exhibited positive results from its Phase III ML18147 study, presented at the American Society of Clinical Oncology, reduced death risk by 19 percent with the median overall survival at 11.2 months compared with 9.8 months for patients who did not receive Avastin in combination with their chemotherapy procedures, said Genentech in a statement.

Also, Avastin reduced progression free survival or PFS-the risk of the cancer worsening or death progression-by 32 percent, with median PFS at 5.7 months compared to 4.1 months in the Avastin free treatment methodology.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Burger chain Shake Shack Inc. said late Thursday that it has priced its initial public offering of 5 million Class A shares at $21 per share, which is above the previously estimated price range of $17 to $19 per share. The shares are expected to begin trading on the New York Stock Exchange on Friday, January 30 under the ticker symbol "SHAK." Google reported a higher fourth-quarter profit, driven by a 15 percent increase in revenues and one-time gains from the sale of Motorola Mobile business, somewhat offset by stock-based compensation expense and foreign exchange losses. Quarterly earnings and revenue missed Wall Street estimates, as ad revenues came under pressure. Online retailer Amazon.com, Inc. said Thursday after the markets closed that its fourth quarter fell 10.5% from last year, as higher expenses more than offset a 15% increase in sales. However, the company's quarterly earnings per share came in well above analysts' expectation, but its quarterly sales fell short of analysts' forecast.
comments powered by Disqus
Follow RTT